<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:base="http://www.plosone.org/">
  <title type="text">PLoS ONE Alerts: Pharmacology</title>
  <link rel="self" href="http://www.plosone.org/" title="PLoS ONE" />
  <author>
    <name>PLoS</name>
    <uri>http://www.plosone.org/</uri>
    <email>webmaster@plos.org</email>
  </author>
  <subtitle>Publishing science</subtitle>
  <id>info:doi/10.1371/feed.pone?category=Pharmacology</id>
  <rights>This work is licensed under a Creative Commons Attribution-Share Alike 3.0 License</rights>
  <icon>${webserver-url}images/favicon.ico</icon>
  <logo>${webserver-url}images/favicon.ico</logo>
  <updated>2009-11-22T06:13:28Z</updated>
  <atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com" /><entry>
    <title>Role of Serotonin via 5-HT&lt;sub&gt;2B&lt;/sub&gt; Receptors in the Reinforcing Effects of MDMA in Mice</title>
    <link rel="alternate" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007952" title="Role of Serotonin via 5-HT&lt;sub&gt;2B&lt;/sub&gt; Receptors in the Reinforcing Effects of MDMA in Mice" />
    <link rel="related" type="text/xml" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007952&amp;representation=XML" title="(XML) Role of Serotonin via 5-HT&lt;sub&gt;2B&lt;/sub&gt; Receptors in the Reinforcing Effects of MDMA in Mice" />
    <link rel="related" type="application/pdf" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007952&amp;representation=PDF" title="(PDF) Role of Serotonin via 5-HT&lt;sub&gt;2B&lt;/sub&gt; Receptors in the Reinforcing Effects of MDMA in Mice" />
    <author>
      <name>Stéphane Doly et al.</name>
    </author>
    <id>info:doi/10.1371/journal.pone.0007952</id>
    <updated>2009-11-23T08:00:00Z</updated>
    <published>2009-11-23T08:00:00Z</published>
    <content type="html">&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;The amphetamine derivative 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) reverses dopamine and serotonin transporters to produce efflux of dopamine and serotonin, respectively, in regions of the brain that have been implicated in reward. However, the role of serotonin/dopamine interactions in the behavioral effects of MDMA remains unclear. We previously showed that MDMA-induced locomotion, serotonin and dopamine release are 5-HT&lt;sub&gt;2B&lt;/sub&gt; receptor-dependent. The aim of the present study was to determine the contribution of serotonin and 5-HT&lt;sub&gt;2B&lt;/sub&gt; receptors to the reinforcing properties of MDMA.&lt;/p&gt;
&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;We show here that 5-HT&lt;sub&gt;2B&lt;/sub&gt;&lt;sup&gt;−/−&lt;/sup&gt; mice do not exhibit behavioral sensitization or conditioned place preference following MDMA (10 mg/kg) injections. In addition, MDMA-induced reinstatement of conditioned place preference after extinction and locomotor sensitization development are each abolished by a 5-HT&lt;sub&gt;2B&lt;/sub&gt; receptor antagonist (RS127445) in wild type mice. Accordingly, MDMA-induced dopamine D1 receptor-dependent phosphorylation of extracellular regulated kinase in nucleus accumbens is abolished in mice lacking functional 5-HT&lt;sub&gt;2B&lt;/sub&gt; receptors. Nevertheless, high doses (30 mg/kg) of MDMA induce dopamine-dependent but serotonin and 5-HT&lt;sub&gt;2B&lt;/sub&gt; receptor-independent behavioral effects.&lt;/p&gt;
&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;These results underpin the importance of 5-HT&lt;sub&gt;2B&lt;/sub&gt; receptors in the reinforcing properties of MDMA and illustrate the importance of dose-dependent effects of MDMA on serotonin/dopamine interactions.&lt;/p&gt;</content>
  </entry>
  <entry>
    <title>Pharmacological Alterations of Anxious Behaviour in Mice Depending on Both Strain and the Behavioural Situation</title>
    <link rel="alternate" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007745" title="Pharmacological Alterations of Anxious Behaviour in Mice Depending on Both Strain and the Behavioural Situation" />
    <link rel="related" type="text/xml" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007745&amp;representation=XML" title="(XML) Pharmacological Alterations of Anxious Behaviour in Mice Depending on Both Strain and the Behavioural Situation" />
    <link rel="related" type="application/pdf" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007745&amp;representation=PDF" title="(PDF) Pharmacological Alterations of Anxious Behaviour in Mice Depending on Both Strain and the Behavioural Situation" />
    <author>
      <name>Yan Clément et al.</name>
    </author>
    <id>info:doi/10.1371/journal.pone.0007745</id>
    <updated>2009-11-11T08:00:00Z</updated>
    <published>2009-11-11T08:00:00Z</published>
    <content type="html">&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;A previous study comparing non-emotive mice from the strain C57BL/6/ByJ with ABP/Le mice showed ABP/Le to be more anxious in an open-field situation. In the present study, several compounds affecting anxiety were assayed on ABP/Le and C57BL/6/ByJ mice using three behavioural models of anxiety: the elevated plus-maze, the light-dark discrimination test and the free exploratory paradigm. The compounds used were the full benzodiazepine receptor agonist, chlordiazepoxide, and the antagonist, flumazenil, the GABA&lt;sub&gt;A&lt;/sub&gt; antagonist, bicuculline, the full 5-HT&lt;sub&gt;1A&lt;/sub&gt; agonist 8-OH-DPAT, and the mixed 5-HT&lt;sub&gt;1A&lt;/sub&gt;/5-HT&lt;sub&gt;1B&lt;/sub&gt; agonist, RU 24969. Results showed the effect of the compounds to be dependent on both the strain and the behavioural task. Several compounds found to be anxiolytic in ABP/Le mice had an anxiogenic effect on C57BL/6/ByJ mice. More behavioural changes were observed for ABP/Le in the elevated plus-maze, but the clearest findings for C57BL/6/ByJ mice were observed in the light-dark discrimination apparatus. These data demonstrate that anxious behaviour is a complex phenomenon which cannot be described by a single behavioural task nor by the action of a single compound.&lt;/p&gt;</content>
  </entry>
  <entry>
    <title>Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers</title>
    <link rel="alternate" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007765" title="Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers" />
    <link rel="related" type="application/pdf" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007765&amp;representation=PDF" title="(PDF) Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers" />
    <link rel="related" type="text/xml" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007765&amp;representation=XML" title="(XML) Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers" />
    <author>
      <name>Liang Li et al.</name>
    </author>
    <id>info:doi/10.1371/journal.pone.0007765</id>
    <updated>2009-11-09T08:00:00Z</updated>
    <published>2009-11-09T08:00:00Z</published>
    <content type="html">&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Cancer patients show large individual variation in their response to chemotherapeutic agents. Gemcitabine (dFdC) and AraC, two cytidine analogues, have shown significant activity against a variety of tumors. We previously used expression data from a lymphoblastoid cell line-based model system to identify genes that might be important for the two drug cytotoxicity. In the present study, we used that same model system to perform a genome-wide association (GWA) study to test the hypothesis that common genetic variation might influence both gene expression and response to the two drugs. Specifically, genome-wide single nucleotide polymorphisms (SNPs) and mRNA expression data were obtained using the Illumina 550K® HumanHap550 SNP Chip and Affymetrix U133 Plus 2.0 GeneChip, respectively, for 174 ethnically-defined “Human Variation Panel” lymphoblastoid cell lines. Gemcitabine and AraC cytotoxicity assays were performed to obtain IC&lt;sub&gt;50&lt;/sub&gt; values for the cell lines. We then performed GWA studies with SNPs, gene expression and IC&lt;sub&gt;50&lt;/sub&gt; of these two drugs. This approach identified SNPs that were associated with gemcitabine or AraC IC&lt;sub&gt;50&lt;/sub&gt; values and with the expression regulation for 29 genes or 30 genes, respectively. One SNP in &lt;i&gt;IQGAP2&lt;/i&gt; (rs3797418) was significantly associated with variation in both the expression of multiple genes and gemcitabine and AraC IC&lt;sub&gt;50&lt;/sub&gt;. A second SNP in &lt;i&gt;TGM3&lt;/i&gt; (rs6082527) was also significantly associated with multiple gene expression and gemcitabine IC50. To confirm the association results, we performed siRNA knock down of selected genes with expression that was associated with rs3797418 and rs6082527 in tumor cell and the knock down altered gemcitabine or AraC sensitivity, confirming our association study results. These results suggest that the application of GWA approaches using cell-based model systems, when combined with complementary functional validation, can provide insights into mechanisms responsible for variation in cytidine analogue response.&lt;/p&gt;</content>
  </entry>
  <entry>
    <title>Novel Pandemic Influenza A(H1N1) Viruses Are Potently Inhibited by DAS181, a Sialidase Fusion Protein</title>
    <link rel="alternate" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007788" title="Novel Pandemic Influenza A(H1N1) Viruses Are Potently Inhibited by DAS181, a Sialidase Fusion Protein" />
    <link rel="related" type="text/xml" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007788&amp;representation=XML" title="(XML) Novel Pandemic Influenza A(H1N1) Viruses Are Potently Inhibited by DAS181, a Sialidase Fusion Protein" />
    <link rel="related" type="application/pdf" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007788&amp;representation=PDF" title="(PDF) Novel Pandemic Influenza A(H1N1) Viruses Are Potently Inhibited by DAS181, a Sialidase Fusion Protein" />
    <author>
      <name>Gallen B. Triana-Baltzer et al.</name>
    </author>
    <id>info:doi/10.1371/journal.pone.0007788</id>
    <updated>2009-11-06T08:00:00Z</updated>
    <published>2009-11-06T08:00:00Z</published>
    <content type="html">Background

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;The recent emergence of a novel pandemic influenza A(H1N1) strain in humans exemplifies the rapid and unpredictable nature of influenza virus evolution and the need for effective therapeutics and vaccines to control such outbreaks. However, resistance to antivirals can be a formidable problem as evidenced by the currently widespread oseltamivir- and adamantane-resistant seasonal influenza A viruses (IFV). Additional antiviral approaches with novel mechanisms of action are needed to combat novel and resistant influenza strains. DAS181 (Fludase™) is a sialidase fusion protein in early clinical development with &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt; preclinical activity against a variety of seasonal influenza strains and highly pathogenic avian influenza strains (A/H5N1). Here, we use &lt;i&gt;in vitro&lt;/i&gt;, &lt;i&gt;ex vivo&lt;/i&gt;, and &lt;i&gt;in vivo&lt;/i&gt; models to evaluate the activity of DAS181 against several pandemic influenza A(H1N1) viruses.&lt;/p&gt;

Methods and Findings

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;The activity of DAS181 against several pandemic influenza A(H1N1) virus isolates was examined in MDCK cells, differentiated primary human respiratory tract culture, &lt;i&gt;ex-vivo&lt;/i&gt; human bronchi tissue and mice. DAS181 efficiently inhibited viral replication in each of these models and against all tested pandemic influenza A(H1N1) strains. DAS181 treatment also protected mice from pandemic influenza A(H1N1)-induced pathogenesis. Furthermore, DAS181 antiviral activity against pandemic influenza A(H1N1) strains was comparable to that observed against seasonal influenza virus including the H274Y oseltamivir-resistant influenza virus.&lt;/p&gt;

Conclusions

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;The sialidase fusion protein DAS181 exhibits potent inhibitory activity against pandemic influenza A(H1N1) viruses. As inhibition was also observed with oseltamivir-resistant IFV (H274Y), DAS181 may be active against the antigenically novel pandemic influenza A(H1N1) virus should it acquire the H274Y mutation. Based on these and previous results demonstrating DAS181 broad-spectrum anti-IFV activity, DAS181 represents a potential therapeutic agent for prevention and treatment of infections by both emerging and seasonal strains of IFV.&lt;/p&gt;</content>
  </entry>
  <entry>
    <title>Zicam-Induced Damage to Mouse and Human Nasal Tissue</title>
    <link rel="alternate" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007647" title="Zicam-Induced Damage to Mouse and Human Nasal Tissue" />
    <link rel="related" type="text/xml" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007647&amp;representation=XML" title="(XML) Zicam-Induced Damage to Mouse and Human Nasal Tissue" />
    <link rel="related" type="application/pdf" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007647&amp;representation=PDF" title="(PDF) Zicam-Induced Damage to Mouse and Human Nasal Tissue" />
    <author>
      <name>Jae H. Lim et al.</name>
    </author>
    <id>info:doi/10.1371/journal.pone.0007647</id>
    <updated>2009-10-30T07:00:00Z</updated>
    <published>2009-10-30T07:00:00Z</published>
    <content type="html">&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Intranasal medications are used to treat various nasal disorders. However, their effects on olfaction remain unknown. Zicam (zinc gluconate; Matrixx Initiatives, Inc), a homeopathic substance marketed to alleviate cold symptoms, has been implicated in olfactory dysfunction. Here, we investigated Zicam and several common intranasal agents for their effects on olfactory function. Zicam was the only substance that showed significant cytotoxicity in both mouse and human nasal tissue. Specifically, Zicam-treated mice had disrupted sensitivity of olfactory sensory neurons to odorant stimulation and were unable to detect novel odorants in behavioral testing. These findings were long-term as no recovery of function was observed after two months. Finally, human nasal explants treated with Zicam displayed significantly elevated extracellular lactate dehydrogenase levels compared to saline-treated controls, suggesting severe necrosis that was confirmed on histology. Our results demonstrate that Zicam use could irreversibly damage mouse and human nasal tissue and may lead to significant smell dysfunction.&lt;/p&gt;</content>
  </entry>
  <entry>
    <title>Heme Mediates Cytotoxicity from Artemisinin and Serves as a General Anti-Proliferation Target</title>
    <link rel="alternate" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007472" title="Heme Mediates Cytotoxicity from Artemisinin and Serves as a General Anti-Proliferation Target" />
    <link rel="related" type="text/xml" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007472&amp;representation=XML" title="(XML) Heme Mediates Cytotoxicity from Artemisinin and Serves as a General Anti-Proliferation Target" />
    <link rel="related" type="application/pdf" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007472&amp;representation=PDF" title="(PDF) Heme Mediates Cytotoxicity from Artemisinin and Serves as a General Anti-Proliferation Target" />
    <author>
      <name>Shiming Zhang et al.</name>
    </author>
    <id>info:doi/10.1371/journal.pone.0007472</id>
    <updated>2009-10-28T07:00:00Z</updated>
    <published>2009-10-28T07:00:00Z</published>
    <content type="html">&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Heme (Fe2+ protoporphyrin IX) is an essential molecule that has been implicated the potent antimalarial action of artemisinin and its derivatives, although the source and nature of the heme remain controversial. Artemisinins also exhibit selective cytotoxicity against cancer cells &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt;. We demonstrate that intracellular heme is the physiologically relevant mediator of the cytotoxic effects of artemisinins. Increasing intracellular heme synthesis through the addition of aminolevulinic acid, protoporphyrin IX, or transferrin-bound iron increased the cytotoxicity of dihydroartemisinin, while decreasing heme synthesis through the addition of succinyl acetone decreased its cytotoxic activity. A simple and robust high throughput assay was developed to screen chemical compounds that were capable of interacting with heme. A natural products library was screened which identified the compound coralyne, in addition to artemisinin, as a heme interacting compound with heme synthesis dependent cytotoxic activity. These results indicate that cellular heme may serve a general target for the development of both anti-parasitic and anti-cancer therapeutics.&lt;/p&gt;</content>
  </entry>
  <entry>
    <title>Potencies of Cocaine Methiodide on Major Cocaine Targets in Mice</title>
    <link rel="alternate" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007578" title="Potencies of Cocaine Methiodide on Major Cocaine Targets in Mice" />
    <link rel="related" type="text/xml" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007578&amp;representation=XML" title="(XML) Potencies of Cocaine Methiodide on Major Cocaine Targets in Mice" />
    <link rel="related" type="application/pdf" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007578&amp;representation=PDF" title="(PDF) Potencies of Cocaine Methiodide on Major Cocaine Targets in Mice" />
    <author>
      <name>Erik R. Hill et al.</name>
    </author>
    <id>info:doi/10.1371/journal.pone.0007578</id>
    <updated>2009-10-26T07:00:00Z</updated>
    <published>2009-10-26T07:00:00Z</published>
    <content type="html">&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Cocaine methiodide (CM), a charged cocaine analog, cannot pass the blood brain barrier. It has been assumed the effects of systemic CM represent cocaine actions in peripheral tissues. However, the IC&lt;sub&gt;50&lt;/sub&gt; values of CM have not been clearly determined for the major cocaine targets: dopamine, norepinephrine, and serotonin transporters, and sodium channels. Using cells transfected with individual transporters from mice and synaptosomes from mouse striatum tissues, we observed that the inhibition IC&lt;sub&gt;50&lt;/sub&gt; values for monoamine uptake by CM were 31-fold to 184-fold higher compared to cocaine at each of the transporters. In dorsal root ganglion neurons, cocaine inhibited sodium channels with an apparent IC&lt;sub&gt;50&lt;/sub&gt; of 75 µM, while CM showed no observable effect at concentrations up to 3 mM. These results indicate that an equal dose of CM will not produce an equivalent peripheral effect of cocaine.&lt;/p&gt;</content>
  </entry>
  <entry>
    <title>Hypothermia and Postconditioning after Cardiopulmonary Resuscitation Reduce Cardiac Dysfunction by Modulating Inflammation, Apoptosis and Remodeling</title>
    <link rel="alternate" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007588" title="Hypothermia and Postconditioning after Cardiopulmonary Resuscitation Reduce Cardiac Dysfunction by Modulating Inflammation, Apoptosis and Remodeling" />
    <link rel="related" type="application/pdf" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007588&amp;representation=PDF" title="(PDF) Hypothermia and Postconditioning after Cardiopulmonary Resuscitation Reduce Cardiac Dysfunction by Modulating Inflammation, Apoptosis and Remodeling" />
    <link rel="related" type="text/xml" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007588&amp;representation=XML" title="(XML) Hypothermia and Postconditioning after Cardiopulmonary Resuscitation Reduce Cardiac Dysfunction by Modulating Inflammation, Apoptosis and Remodeling" />
    <author>
      <name>Patrick Meybohm et al.</name>
    </author>
    <id>info:doi/10.1371/journal.pone.0007588</id>
    <updated>2009-10-26T07:00:00Z</updated>
    <published>2009-10-26T07:00:00Z</published>
    <content type="html">Background

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Mild therapeutic hypothermia following cardiac arrest is neuroprotective, but its effect on myocardial dysfunction that is a critical issue following resuscitation is not clear. This study sought to examine whether hypothermia and the combination of hypothermia and pharmacological postconditioning are cardioprotective in a model of cardiopulmonary resuscitation following acute myocardial ischemia.&lt;/p&gt;

Methodology/Principal Findings

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Thirty pigs (28–34 kg) were subjected to cardiac arrest following left anterior descending coronary artery ischemia. After 7 minutes of ventricular fibrillation and 2 minutes of basic life support, advanced cardiac life support was started according to the current AHA guidelines. After successful return of spontaneous circulation (n = 21), coronary perfusion was reestablished after 60 minutes of occlusion, and animals were randomized to either normothermia at 38°C, hypothermia at 33°C or hypothermia at 33°C combined with sevoflurane (each group n = 7) for 24 hours. The effects on cardiac damage especially on inflammation, apoptosis, and remodeling were studied using cellular and molecular approaches. Five animals were sham operated. Animals treated with hypothermia had lower troponin T levels (p&amp;lt;0.01), reduced infarct size (34±7 versus 57±12%; p&amp;lt;0.05) and improved left ventricular function compared to normothermia (p&amp;lt;0.05). Hypothermia was associated with a reduction in: (i) immune cell infiltration, (ii) apoptosis, (iii) IL-1β and IL-6 mRNA up-regulation, and (iv) IL-1β protein expression (p&amp;lt;0.05). Moreover, decreased matrix metalloproteinase-9 activity was detected in the ischemic myocardium after treatment with mild hypothermia. Sevoflurane conferred additional protective effects although statistic significance was not reached.&lt;/p&gt;

Conclusions/Significance

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Hypothermia reduced myocardial damage and dysfunction after cardiopulmonary resuscitation possible via a reduced rate of apoptosis and pro-inflammatory cytokine expression.&lt;/p&gt;</content>
  </entry>
  <entry>
    <title>Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)</title>
    <link rel="alternate" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007520" title="Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)" />
    <link rel="related" type="text/xml" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007520&amp;representation=XML" title="(XML) Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)" />
    <link rel="related" type="application/pdf" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007520&amp;representation=PDF" title="(PDF) Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)" />
    <author>
      <name>Tong Shen et al.</name>
    </author>
    <id>info:doi/10.1371/journal.pone.0007520</id>
    <updated>2009-10-20T07:00:00Z</updated>
    <published>2009-10-20T07:00:00Z</published>
    <content type="html">Background

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;One of the major mechanisms that could produce resistance to antineoplastic drugs in cancer cells is the ATP binding cassette (ABC) transporters. The ABC transporters can significantly decrease the intracellular concentration of antineoplastic drugs by increasing their efflux, thereby lowering the cytotoxic activity of antineoplastic drugs. One of these transporters, the multiple resistant protein 7 (MRP7, ABCC10), has recently been shown to produce resistance to antineoplastic drugs by increasing the efflux of paclitaxel. In this study, we examined the effects of BCR-Abl tyrosine kinase inhibitors imatinib, nilotinib and dasatinib on the activity and expression of MRP7 in HEK293 cells transfected with MRP7, designated HEK-MRP7-2.&lt;/p&gt;

Methodology and/or Principal Findings

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;We report for the first time that imatinib and nilotinib reversed MRP7-mediated multidrug resistance. Our MTT assay results indicated that MRP7 expression in HEK-MRP7-2 cells was not significantly altered by incubation with 5 µM of imatinib or nilotinib for up to 72 hours. In addition, imatinib and nilotinib (1-5 µM) produced a significant concentration-dependent reversal of MRP7-mediated multidrug resistance by enhancing the sensitivity of HEK-MRP7-2 cells to paclitaxel and vincristine. Imatinib and nilotinib, at 5 µM, significantly increased the accumulation of [&lt;sup&gt;3&lt;/sup&gt;H]-paclitaxel in HEK-MRP7-2 cells. The incubation of the HEK-MRP7-2 cells with imatinib or nilotinib (5 µM) also significantly inhibited the efflux of paclitaxel.&lt;/p&gt;

Conclusions

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Imatinib and nilotinib reverse MRP7-mediated paclitaxel resistance, most likely due to their inhibition of the efflux of paclitaxel via MRP7. These findings suggest that imatinib or nilotinib, in combination with other antineoplastic drugs, may be useful in the treatment of certain resistant cancers.&lt;/p&gt;</content>
  </entry>
  <entry>
    <title>Empirical Bayes Analysis of Quantitative Proteomics Experiments</title>
    <link rel="alternate" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007454" title="Empirical Bayes Analysis of Quantitative Proteomics Experiments" />
    <link rel="related" type="text/xml" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007454&amp;representation=XML" title="(XML) Empirical Bayes Analysis of Quantitative Proteomics Experiments" />
    <link rel="related" type="application/pdf" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007454&amp;representation=PDF" title="(PDF) Empirical Bayes Analysis of Quantitative Proteomics Experiments" />
    <author>
      <name>Adam A. Margolin et al.</name>
    </author>
    <id>info:doi/10.1371/journal.pone.0007454</id>
    <updated>2009-10-14T07:00:00Z</updated>
    <published>2009-10-14T07:00:00Z</published>
    <content type="html">Background

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Advances in mass spectrometry-based proteomics have enabled the incorporation of proteomic data into systems approaches to biology. However, development of analytical methods has lagged behind. Here we describe an empirical Bayes framework for quantitative proteomics data analysis. The method provides a statistical description of each experiment, including the number of proteins that differ in abundance between 2 samples, the experiment's statistical power to detect them, and the false-positive probability of each protein.&lt;/p&gt;

Methodology/Principal Findings

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;We analyzed 2 types of mass spectrometric experiments. First, we showed that the method identified the protein targets of small-molecules in affinity purification experiments with high precision. Second, we re-analyzed a mass spectrometric data set designed to identify proteins regulated by microRNAs. Our results were supported by sequence analysis of the 3′ UTR regions of predicted target genes, and we found that the previously reported conclusion that a large fraction of the proteome is regulated by microRNAs was not supported by our statistical analysis of the data.&lt;/p&gt;

Conclusions/Significance

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Our results highlight the importance of rigorous statistical analysis of proteomic data, and the method described here provides a statistical framework to robustly and reliably interpret such data.&lt;/p&gt;</content>
  </entry>
  <entry>
    <title>The Epoxygenases CYP2J2 Activates the Nuclear Receptor PPARα &lt;italic&gt;In Vitro&lt;/italic&gt; and &lt;italic&gt;In Vivo&lt;/italic&gt;</title>
    <link rel="alternate" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007421" title="The Epoxygenases CYP2J2 Activates the Nuclear Receptor PPARα &lt;italic&gt;In Vitro&lt;/italic&gt; and &lt;italic&gt;In Vivo&lt;/italic&gt;" />
    <link rel="related" type="text/xml" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007421&amp;representation=XML" title="(XML) The Epoxygenases CYP2J2 Activates the Nuclear Receptor PPARα &lt;italic&gt;In Vitro&lt;/italic&gt; and &lt;italic&gt;In Vivo&lt;/italic&gt;" />
    <link rel="related" type="application/pdf" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007421&amp;representation=PDF" title="(PDF) The Epoxygenases CYP2J2 Activates the Nuclear Receptor PPARα &lt;italic&gt;In Vitro&lt;/italic&gt; and &lt;italic&gt;In Vivo&lt;/italic&gt;" />
    <author>
      <name>Jessica A. Wray et al.</name>
    </author>
    <id>info:doi/10.1371/journal.pone.0007421</id>
    <updated>2009-10-12T07:00:00Z</updated>
    <published>2009-10-12T07:00:00Z</published>
    <content type="html">Background

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Peroxisome proliferator-activated receptors (PPARs) are a family of three (PPARα, -β/δ, and -γ) nuclear receptors. In particular, PPARα is involved in regulation of fatty acid metabolism, cell growth and inflammation. PPARα mediates the cardiac fasting response, increasing fatty acid metabolism, decreasing glucose utilisation, and is the target for the fibrate lipid-lowering class of drugs. However, little is known regarding the endogenous generation of PPAR ligands. CYP2J2 is a lipid metabolising cytochrome P450, which produces anti-inflammatory mediators, and is considered the major epoxygenase in the human heart.&lt;/p&gt;

Methodology/Principal Findings

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Expression of CYP2J2 &lt;i&gt;in vitro&lt;/i&gt; results in an activation of PPAR responses with a particular preference for PPARα. The CYP2J2 products 8,9- and 11-12-EET also activate PPARα. In vitro, PPARα activation by its selective ligand induces the PPARα target gene pyruvate dehydrogenase kinase (PDK)4 in cardiac tissue. I&lt;i&gt;n vivo&lt;/i&gt;, in cardiac-specific CYP2J2 transgenic mice, fasting selectively augments the expression of PDK4.&lt;/p&gt;

Conclusions/Significance

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Our results establish that CYP2J2 produces PPARα ligands &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt;, and suggests that lipid metabolising CYPs are prime candidates for the integration of global lipid changes to transcriptional signalling events.&lt;/p&gt;</content>
  </entry>
  <entry>
    <title>Identification of a Novel Topoisomerase Inhibitor Effective in Cells Overexpressing Drug Efflux Transporters</title>
    <link rel="alternate" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007238" title="Identification of a Novel Topoisomerase Inhibitor Effective in Cells Overexpressing Drug Efflux Transporters" />
    <link rel="related" type="application/pdf" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007238&amp;representation=PDF" title="(PDF) Identification of a Novel Topoisomerase Inhibitor Effective in Cells Overexpressing Drug Efflux Transporters" />
    <link rel="related" type="text/xml" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007238&amp;representation=XML" title="(XML) Identification of a Novel Topoisomerase Inhibitor Effective in Cells Overexpressing Drug Efflux Transporters" />
    <author>
      <name>Walid Fayad et al.</name>
    </author>
    <id>info:doi/10.1371/journal.pone.0007238</id>
    <updated>2009-10-02T07:00:00Z</updated>
    <published>2009-10-02T07:00:00Z</published>
    <content type="html">Background

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Natural product structures have high chemical diversity and are attractive as lead structures for discovery of new drugs. One of the disease areas where natural products are most frequently used as therapeutics is oncology.&lt;/p&gt;

Method and Findings

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;A library of natural products (NCI Natural Product set) was screened for compounds that induce apoptosis of HCT116 colon carcinoma cells using an assay that measures an endogenous caspase-cleavage product. One of the apoptosis-inducing compounds identified in the screen was thaspine (taspine), an alkaloid from the South American tree &lt;i&gt;Croton lechleri&lt;/i&gt;. The cortex of this tree is used for medicinal purposes by tribes in the Amazonas basin. Thaspine was found to induce conformational activation of the pro-apoptotic proteins Bak and Bax, mitochondrial cytochrome c release and mitochondrial membrane permeabilization in HCT116 cells. Analysis of the gene expression signature of thaspine-treated cells suggested that thaspine is a topoisomerase inhibitor. Inhibition of both topoisomerase I and II was observed using &lt;i&gt;in vitro&lt;/i&gt; assays, and thaspine was found to have a reduced cytotoxic effect on a cell line with a mutated topoisomerase II enzyme. Interestingly, in contrast to the topoisomerase II inhibitors doxorubicin, etoposide and mitoxantrone, thaspine was cytotoxic to cell lines overexpressing the PgP or MRP drug efflux transporters. We finally show that thaspine induces wide-spread apoptosis in colon carcinoma multicellular spheroids and that apoptosis is induced in two xenograft mouse models &lt;i&gt;in vivo&lt;/i&gt;.&lt;/p&gt;

Conclusions

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;The alkaloid thaspine from the cortex of &lt;i&gt;Croton lechleri&lt;/i&gt; is a dual topoisomerase inhibitor effective in cells overexpressing drug efflux transporters and induces wide-spread apoptosis in multicellular spheroids.&lt;/p&gt;</content>
  </entry>
  <entry>
    <title>An Efficient Targeted Drug Delivery through Apotransferrin Loaded Nanoparticles</title>
    <link rel="alternate" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007240" title="An Efficient Targeted Drug Delivery through Apotransferrin Loaded Nanoparticles" />
    <link rel="related" type="application/pdf" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007240&amp;representation=PDF" title="(PDF) An Efficient Targeted Drug Delivery through Apotransferrin Loaded Nanoparticles" />
    <link rel="related" type="text/xml" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007240&amp;representation=XML" title="(XML) An Efficient Targeted Drug Delivery through Apotransferrin Loaded Nanoparticles" />
    <author>
      <name>Athuluri Divakar Sai Krishna et al.</name>
    </author>
    <id>info:doi/10.1371/journal.pone.0007240</id>
    <updated>2009-10-02T07:00:00Z</updated>
    <published>2009-10-02T07:00:00Z</published>
    <content type="html">Background

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Cancerous state is a highly stimulated environment of metabolically active cells. The cells under these conditions over express selective receptors for assimilation of factors essential for growth and transformation. Such receptors would serve as potential targets for the specific ligand mediated transport of pharmaceutically active molecules. The present study demonstrates the specificity and efficacy of protein nanoparticle of apotransferrin for targeted delivery of doxorubicin.&lt;/p&gt;

Methodology/Principal Findings

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Apotransferrin nanoparticles were developed by sol-oil chemistry. A comparative analysis of efficiency of drug delivery in conjugated and non-conjugated forms of doxorubicin to apotransferrin nanoparticle is presented. The spherical shaped apotransferrin nanoparticles (nano) have diameters of 25–50 ηm, which increase to 60–80 ηm upon direct loading of drug (direct-nano), and showed further increase in dimension (75–95 ηm) in conjugated nanoparticles (conj-nano). The competitive experiments with the transferrin receptor specific antibody showed the entry of both conj-nano and direct-nano into the cells through transferrin receptor mediated endocytosis. Results of various studies conducted clearly establish the superiority of the direct-nano over conj-nano viz. (a) localization studies showed complete release of drug very early, even as early as 30 min after treatment, with the drug localizing in the target organelle (nucleus) (b) pharmacokinetic studies showed enhanced drug concentrations, in circulation with sustainable half-life (c) the studies also demonstrated efficient drug delivery, and an enhanced inhibition of proliferation in cancer cells. Tissue distribution analysis showed intravenous administration of direct nano lead to higher drug localization in liver, and blood as compared to relatively lesser localization in heart, kidney and spleen. Experiments using rat cancer model confirmed the efficacy of the formulation in regression of hepatocellular carcinoma with negligible toxicity to kidney and liver.&lt;/p&gt;

Conclusions

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;The present study thus demonstrates that the direct-nano is highly efficacious in delivery of drug in a target specific manner with lower toxicity to heart, liver and kidney.&lt;/p&gt;</content>
  </entry>
  <entry>
    <title>Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer</title>
    <link rel="alternate" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007287" title="Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer" />
    <link rel="related" type="application/pdf" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007287&amp;representation=PDF" title="(PDF) Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer" />
    <link rel="related" type="text/xml" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007287&amp;representation=XML" title="(XML) Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer" />
    <author>
      <name>Andrea Sartore-Bianchi et al.</name>
    </author>
    <id>info:doi/10.1371/journal.pone.0007287</id>
    <updated>2009-10-02T07:00:00Z</updated>
    <published>2009-10-02T07:00:00Z</published>
    <content type="html">Background

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;&lt;i&gt;KRAS&lt;/i&gt; mutations occur in 35–45% of metastatic colorectal cancers (mCRC) and preclude responsiveness to EGFR-targeted therapy with cetuximab or panitumumab. However, less than 20% patients displaying wild-type &lt;i&gt;KRAS&lt;/i&gt; tumors achieve objective response. Alterations in other effectors downstream of the EGFR, such as BRAF, and deregulation of the PIK3CA/PTEN pathway have independently been found to give rise to resistance. We present a comprehensive analysis of &lt;i&gt;KRAS&lt;/i&gt;, &lt;i&gt;BRAF&lt;/i&gt;, &lt;i&gt;PIK3CA&lt;/i&gt; mutations, and PTEN expression in mCRC patients treated with cetuximab or panitumumab, with the aim of clarifying the relative contribution of these molecular alterations to resistance.&lt;/p&gt;

Methodology/Principal Findings

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;We retrospectively analyzed objective tumor response, progression-free (PFS) and overall survival (OS) together with the mutational status of &lt;i&gt;KRAS&lt;/i&gt;, &lt;i&gt;BRAF&lt;/i&gt;, &lt;i&gt;PIK3CA&lt;/i&gt; and expression of PTEN in 132 tumors from cetuximab or panitumumab treated mCRC patients. Among the 106 non-responsive patients, 74 (70%) had tumors with at least one molecular alteration in the four markers. The probability of response was 51% (22/43) among patients with no alterations, 4% (2/47) among patients with 1 alteration, and 0% (0/24) for patients with ≥2 alterations (p&amp;lt;0.0001). Accordingly, PFS and OS were increasingly worse for patients with tumors harboring none, 1, or ≥2 molecular alteration(s) (p&amp;lt;0.001).&lt;/p&gt;

Conclusions/Significance

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;When expression of PTEN and mutations of &lt;i&gt;KRAS&lt;/i&gt;, &lt;i&gt;BRAF&lt;/i&gt; and &lt;i&gt;PIK3CA&lt;/i&gt; are concomitantly ascertained, up to 70% of mCRC patients unlikely to respond to anti-EGFR therapies can be identified. We propose to define as ‘&lt;i&gt;quadruple negative&lt;/i&gt;’, the CRCs lacking alterations in &lt;i&gt;KRAS&lt;/i&gt;, &lt;i&gt;BRAF&lt;/i&gt;, PTEN and &lt;i&gt;PIK3CA&lt;/i&gt;. Comprehensive molecular dissection of the EGFR signaling pathways should be considered to select mCRC patients for cetuximab- or panitumumab-based therapies.&lt;/p&gt;</content>
  </entry>
  <entry>
    <title>Drugs Associated with More Suicidal Ideations Are also Associated with More Suicide Attempts</title>
    <link rel="alternate" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007312" title="Drugs Associated with More Suicidal Ideations Are also Associated with More Suicide Attempts" />
    <link rel="related" type="application/pdf" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007312&amp;representation=PDF" title="(PDF) Drugs Associated with More Suicidal Ideations Are also Associated with More Suicide Attempts" />
    <link rel="related" type="text/xml" href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info:doi/10.1371/journal.pone.0007312&amp;representation=XML" title="(XML) Drugs Associated with More Suicidal Ideations Are also Associated with More Suicide Attempts" />
    <author>
      <name>Henry T. Robertson et al.</name>
    </author>
    <id>info:doi/10.1371/journal.pone.0007312</id>
    <updated>2009-10-02T07:00:00Z</updated>
    <published>2009-10-02T07:00:00Z</published>
    <content type="html">Context

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;In randomized controlled trials (RCTs), some drugs, including CB1 antagonists for obesity treatment, have been shown to cause increased suicidal ideation. A key question is whether drugs that increase or are associated with increased suicidal ideations are also associated with suicidal behavior, or whether drug–induced suicidal ideations are unlinked epiphenomena that do not presage the more troubling and potentially irrevocable outcome of suicidal behavior. This is difficult to determine in RCTs because of the rarity of suicidal attempts and completions.&lt;/p&gt;

Objective

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;To determine whether drugs associated with more suicidal ideations are also associated with more suicide attempts in large spontaneous adverse event (AE) report databases.&lt;/p&gt;

Methodology

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Generalized linear models with negative binomial distribution were fitted to Food and Drug Administration (FDA) Adverse Event (AE) Reporting System (AERS) data from 2004 to 2008. A total of 1,404,470 AEs from 832 drugs were analyzed as a function of reports of suicidal ideations; other non-suicidal adverse reactions; drug class; proportion of reports from males; and average age of subject for which AE was filed. Drug was treated as the unit of analysis, thus the statistical models effectively had 832 observations.&lt;/p&gt;

Main Outcome Measures

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;Reported suicide attempts and completed suicides per drug.&lt;/p&gt;

Results

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;832 drugs, ranging from abacavir to zopiclone, were evaluated. The 832 drugs, as primary suspect drugs in a given adverse event, accounted for over 99.9% of recorded AERS. Suicidal ideations had a significant positive association with suicide attempts (p&amp;lt;.0001) and had an approximately 131-fold stronger magnitude of association than non-suicidal AERs, after adjusting for drug class, gender, and age.&lt;/p&gt;

Conclusions

&lt;p xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:util="http://dtd.nlm.nih.gov/xsl/util" xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;In AE reports, drugs that are associated with increased suicidal ideations are also associated with increased suicidal attempts or completions. This association suggests that drug-induced suicidal ideations observed in RCTs plausibly represent harbingers that presage the more serious suicide attempts and completions and should be a cause for concern.&lt;/p&gt;</content>
  </entry>
</feed>
